CD34 and non-Hodgkin lymphoma: For patients with NHL, the infused dose of hematopoietic SCs has an important impact on engraftment kinetics; a higher mobilization target instead of MM, with an optimal dose of ≥5.0 × 106/kg CD34+ HSCs, could improve engraftment and reduce complications, respiratory and infective [56,57].